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The protective efficacy of human immunodeficiency virus-1 (HIV-1) antibodies (Abs) 
remains mostly correlated with their in vitro neutralizing activity engaging their Fab region. 
However, anti-HIV-1 Abs also mediate a broad array of Fc-mediated effector functions 
including Ab-dependent cellular cytotoxicity (ADCC), which depend primarily on the Ab 
isotype. While ADCC is commonly associated with HIV-1 gp120 envelope-specific IgGs, 
whether IgAs, especially those targeting the HIV-1 gp41 envelope, also mediate ADCC 
remains elusive. Therefore, to assess the capacity of IgA specific for HIV-1 to induce Fcα-
mediated ADCC, we used the gp41 envelope-specific IgA transformed from the broadly 
neutralizing 2F5-IgG we have previously reported to induce ADCC. We demonstrate that 
2F5-IgA engages FcαRI (CD89), expressed on human monocytes used as effector cells, 
to induce the lysis of HIV-1 Clade A- and B-infected target cells by ADCC. Furthermore, 
the 2F5-IgA and 2F5-IgG cooperate to enhance target cells lysis by ADCC. Cooperation 
in ADCC is also observed between 2F5-IgA and the broadly neutralizing 10E8-IgG. 
These results provide a new perspective for IgA in protection against HIV-1 acquisition 
or reservoir eradication and suggest that inducing IgA by vaccination, in particular when 
targeting gp41, in combination with IgG could strengthen protection by complementary 
and cooperative activities with IgG.
Keywords: antibody-dependent cellular cytotoxicity, iga, human immunodeficiency virus-1, human 
immunodeficiency virus envelope protein gp41, mucosal immune system
inTrODUcTiOn
The protective efficacy of antibodies (Abs) to human immunodeficiency virus-1 (HIV-1) remains 
mainly correlated with their in vitro neutralizing activity. However, Abs targeting the virus can also 
mediate a broad array of Fc-mediated effector functions for clearing viral particles and infected 
cells, irrespective of their neutralizing activities (1). One of the most relevant Fc-mediated func-
tion is Ab-dependent cellular cytotoxicity (ADCC) engaging natural killer (NK) cells, monocytes, 
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macrophages, or neutrophils as innate effector cells (2). Hence, 
ADCC is one of the earliest IgG function identified in HIV-
infected individuals (3). Furthermore, we and others showed 
that in HIV-infected subjects who spontaneously control viral 
replication, including Elite Controllers and Long-Term Slow 
Progressors, ADCC-inducing IgGs increased in correlation with 
reduction of AIDS progression (4, 5) and exhibit great breadth in 
ADCC responses (6). IgG-mediating ADCC, frequently detected 
in breast milk, correlates with lack of mother-to-child HIV-1 
transmission (7). Furthermore, in highly exposed but persistently 
seronegative individuals, IgG that preferentially recognized Env 
in its CD4-bound conformation can also mediate ADCC (8).
Antibody-dependent cellular cytotoxicity activity remains 
predominantly studied for non-neutralizing (9) or neutralizing 
(10) IgG targeting gp120, the most variable subunit of the HIV-
1-envelope. Likewise, V1/V2-gp120-specific IgG with ADCC 
activities were induced in the RV144 clinical vaccine trial and 
correlated with reduced risk of infection (11, 12). In contrast, 
ADCC potential of gp41-specific IgG remains understudied, 
despite extensive studies on the ADCC capacity of the non-
neutralizing gp41-specific IgG 98.6, targeting the membrane 
proximal external region (MPER) of the gp41 HIV-1-envelope 
subunit or a conformational epitope (13).
Fc-mediated Ab functions are remarkably complex and 
depend on Ab isotype, subclass, degree of glycosylation, and 
on the distribution of isotype-specific Fc receptors (FcRs) on 
effector cells (14). Hence, like IgG, IgA interacts with effector cell 
surface-expressed FcRs, the best known one being the Fc alpha RI 
(FcαRI/CD89). In turn, IgA mediates a panel of innate immune 
responses including not only ADCC but also phagocytosis and 
cytokine synthesis (15).
The role of IgA in HIV-1 target cell lysis by ADCC remains 
elusive, except one study suggesting an ADCC potential for 
anti-gp120 IgA (16) and none questioning the ADCC activity of 
IgA targeting gp41. Moreover, in the RV144 HIV-1 vaccine trial, 
vaccine-induced anti-gp120 IgAs have been proposed to compete 
with anti-gp120 IgGs, thereby reducing IgG-mediated ADCC 
effector function (17, 18), indicative of a greater affinity of IgA 
than of IgG for gp120. Importantly in these studies, ADCC effec-
tor cells lacked FcαRI/CD89 expression, and therefore intrinsic 
Fcα-dependent ADCC activities of IgA could not be evaluated; 
neither could potential synergy of the two isotypes.
Therefore, understanding respective IgG and IgA antiviral 
functions and focusing on gp41-specific Abs remain key issues 
for the design of an HIV-1 vaccine. Accordingly, we previously 
showed that a prophylactic HIV-1 vaccine based on gp41-
conserved MPER subunits induces gp41-specific IgG and IgA 
that were both correlated with full protection against mucosal 
SHIV-1 infection in non-human primates (19). In vaccinated 
animals, protection correlated with gp41-specific IgG capable of 
ADCC. However, in this instance, the intrinsic gp41-specific IgA 
ADCC activity was not evaluated.
Genetic engineering that allows for comparison of IgG and IgA 
functions by IgG and IgA isotype switching revealed striking differ-
ent biological properties between switched isotypes (20). We have 
previously studied isotype influence using as a model the broadly 
neutralizing anti-HIV Ab 2F5. We demonstrated that, while 
containing identical variable regions, 2F5-IgA2 and 2F5-IgG1 have 
distinctive affinities, fine three-dimensional epitope specificities 
for HIV-1 gp41-MPER, and antiviral functions (21). Although 
the 2F5-IgG is the best example of a gp41-neutralizing Ab able to 
utilize the FcγRI to achieve in vitro ADCC activity in addition to its 
neutralization potential, as we have shown earlier (9), whether IgA 
also mediates Fc-mediated effector functions remains unknown.
Until now, studies on anti-HIV-1 immunity including those 
exploring ADCC have mainly focused on the Clade B subtype 
widespread in Europe and the United States, but responsible for 
less than 15% of infections worldwide. Despite recent studies 
on immune responses against Clade C virus that is widespread 
in Asia and Africa, immunity induced by Clade A virus largely 
present in Eastern Europe and Africa remains understudied, 
although these two latter clades account for almost 60% of HIV-1 
infections worldwide (22).
Here, we investigated whether the 2F5 Ab under IgA isotype 
engages FcαRI/CD89-expressing effector cells to lyse HIV-1+ 
target cell by cross-clade ADCC.
resUlTs
Antibody-dependent cellular cytotoxicity is a mechanism whereby 
an Ab bridges effector and target cells, triggering the release of 
lytic enzymes that lyse the target cell. Cell bridging results from 
binding of the Ab Fc-domain to its cognate FcR at effector cell 
surface and from specific recognition by the Ab Fab-domain of 
its antigen on target cells.
2F5-iga and 2F5-igg Bind to effector cells
To investigate the ADCC potential of 2F5-IgA2 (referred to below 
as 2F5-IgA) and permit comparison with 2F5-IgG1 (referred 
to below as 2F5-IgG), we used human primary monocytes as 
effector cells that express both FcαRI/CD89 and FcγRI/CD64, 
therefore capable of binding both IgA and IgG, and also secrete 
granzymes and perforins for target cell lysis (23, 24). Hence, in 
addition to expressing FcγRI that binds IgG1 and IgG3 and act as 
a potent effector cell to induce ADCC (25–27) and Ab-dependent 
cell phagocytosis (ADCP) (28), myeloid cells including mono-
cytes express the FcαRI that binds to all IgA forms, monomeric 
or dimeric, and equally to isotype 1 and 2 (29). Accordingly, by 
using specific Abs and quantification by flow cytometry, we found 
that >85% of the effector monocytes expressed CD89/FcαRI or 
CD64/FcγRI. In addition, using anti-IgA2 as secondary Ab, we 
found that 2F5-IgA (2.5 µg/ml) bound to FcαRI on 26.5 ± 0.14% 
monocytes, whereas using anti-kappa light chain detection to 
allow for a direct comparison between isotypes, 2F5-IgA and 
2F5-IgG (2.5 µg/ml) bound to FcαRI and FcγRI on 5.0 ± 0.4% 
and 5.0 ± 0.8% human monocytes, respectively (Table 1).
2F5-iga and 2F5-igg Bind to hiV-1 clade 
a- and B-infected Target cells
As target cells, we first used either CD4+T CEM cells that are 
resistant to NK  cells (CEM-NKr)—infected with HIV-1 clade 
B (JR-CSF), as we previously reported when characterizing the 
ADCC potential of 2F5-IgG (9), or green fluorescent protein 
TaBle 1 | P1 Clade A and B-specific 2F5-IgA and IgG binding to effector and target cells.
2F5 antibodies (μg/ml) specific labeling (positive cells%)
anti-human kappa  
light chain
anti-human  
iga
anti-human 
igg
iga igg iga igg
Target cells CEM-Nkr 
coated with
P1-A 2.5 19.0 ± 0.6 59.0 ± 5.8 86.0 ± 2 94.3 ± 1.4
P1-B 2.5 34.0 ± 1.6 39.0 ± 3.6 88.0 ± 1.3 91.3 ± 0.9
P1-C 2.5 1.7 ± 0.1 1.0 ± 0.1 Not tested (nt) nt
Infected Clade B (JR-CSF) 2.5 18.9 ± 1.4 7.2 ± 0.5 16.5 ± 1.2 17.2 ± 1.5
Clade A (92UG031) 2.5 13.1 ± 2.9 10.6 ± 2.4 12.3 ± 2.8 8.2 ± 1.9
Effector cells Monocytes 2.5 5.0 ± 0.4 5.0 ± 0.8 26.5 ± 0.14a 16 ± 0.95b
2F5-IgA and 2F5-IgG were incubated with purified monocytes as effector cells, or P1 Clade A-, B-, and C-coated cells, as target cells, or uncoated cells as negative control for 1 h 
at 4°C. Alternatively, antibodies were incubated with human immunodeficiency virus-1 (HIV-1) Clade B- or Clade A- infected cells or uninfected cells as negative control for 45 min 
at room temperature (RT). Irrelevant IgA and IgG were used as negative controls. Specific binding was detected using either mouse fluorescein isothiocyanate (FITC)-conjugated 
anti-human kappa light chain to allow for direct comparison of both 2F5 isotypes or either FITC- or allophycocyanin (APC)-conjugated anti-human IgA/IgG and analyzed by flow 
cytometry, as indicated in Section “Materials and Methods.” Values represent the percentage of monocytes or P1-coated cells that stain positive for each antibody ± SEM, and 
the percentage of mAb+ cells representing a distinct cell population among infected (Gag+ or GFP+) cells ± SEM (for HIV-1 Clade B- and Clade A-infected target cells, respectively) 
relative to the percentage of HIV-1-infected cells. Binding of 2F5-IgA to uncoated and uninfected cells was negligible. Binding of irrelevant IgA and IgG to P1-coated cells were 
negligible (0.4%) and to infected cells, it was fixed at 1% and substracted from the specific binding values shown in the table. n = 5 independent experiments.
aBinding evaluated using an anti-IgA2 as a secondary antibody.
bBinding evaluated using an anti-IgG as a secondary antibody (9).
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(GFP)-reporter CD4+ T-cells infected with HIV-1 Clade A 
(92UGO31). To allow direct comparison of target cell recognition 
by the two 2F5 isotypes, specific binding was detected using either 
mouse anti-human kappa light chain or alternatively anti-human 
IgA or IgG and quantified by flow cytometry (Table 1). Irrelevant 
IgA and IgG were included as negative controls. For the same 
2F5 Ab concentration (2.5 µg/ml), 2F5-IgA bound HIV-1 Clade 
B-infected cells in higher number than 2F5-IgG (18.9 ±  1.4% 
versus 7.2  ±  0.5%) when detected with anti-human kappa 
light chain, whereas binding was similar (16.5 ±  1.21% versus 
17.2 ± 1.5%) when revealed with anti-human IgA or IgG. Using 
higher concentration (10 µg/ml) did not increase specific binding 
efficiency. Similarly, 2F5-IgA and 2F5-IgG bound to 13.1 ± 2.9% 
and 10.6 ± 2.4% HIV-1 Clade A-infected cells as when detected 
with anti-human kappa light chain, similar values being detected 
with anti-human IgA or IgG (Table  1), respectively. Such low 
HIV-1-infected cell binding values for MPER-specific Abs cor-
respond to those reported by others (10). In this later study as 
in the results reported here, Ab concentrations needed to lyse 
cells by ADCC are much lower than those used to measure Ab 
binding, as often the case with functional tests.
2F5-iga and 2F5-igg Bind to Target cells 
coated with hiV-1 clade a and B gp41 
Peptides
We characterized earlier the P1 peptide (aa 649–684) as an 
extended gp41-MPER peptide encompassing the canonical 2F5 
epitope (ELDKWA on gp41 Clade B) (30). P1 allows for HIV-1 
binding to its mucosal receptor galactosylceramide and mediates 
HIV-1 transcytosis across epithelial cells and uptake by dendritic 
cells (30). Furthermore, we reported earlier that the structures of 
the 2F5-specific epitope when complexed to 2F5-IgG and within 
P1, as we defined by NMR, are similar, which is not the case within 
shorter MPER fragments (31). Thus, P1 appears as an optimized 
gp41-derived subunit mimicking the MPER conformation within 
HIV envelope and suitable to be used as a vaccine immunogen in 
order to induce HIV-blocking Abs. Hence, we also used P1 pep-
tide as a gp41-derived immunogen in a clinical vaccine strategy in 
humans (32) that allowed full protection against viral challenges 
in the monkey. Furthermore, in vivo protection in monkey cor-
related with P1-specific IgG capable of mediating ADCC (19). We 
thus used HIV-1 envelope subunit P1 derived from HIV-1 Clade 
A (P1-A), Clade B (P1-B), and Clade C (P1-C) to coat CEM-NKr 
cells as an alternative target cell model, a procedure commonly 
used in ADCC studies (9, 19, 33–35).
First, we characterized the interaction of 2F5-IgA and 2F5-IgG 
with P1-A, P1-B, and P1-C using ELISA. We have previously 
shown that 2F5-IgA and 2F5-IgG bind to P1-B (21). Here, we 
found that both 2F5-IgA and 2F5-IgG specifically bound to P1-B 
and P1-A dose dependently, but not to P1-C (Figures  1A,B). 
2F5-IgA bound P1-B more efficiently than 2F5-IgG, but the 
latter bound P1-A slightly better than 2F5-IgA. 2F5-IgA did not 
recognize P1-C as expected, since the 2F5-IgG canonical epitope 
ELDKWA in Clade B gp41 is mutated to ALDSWK in Clade C 
gp41, a motif not recognized by 2F5-IgG (36).
Next, CEM-NKr target cells were coated with P1-A, P1-B, 
or P1-C, and specific recognition by 2F5-IgA and 2F5-IgG was 
measured using flow cytometry (Table 1). 2F5-IgA or 2F5-IgG 
(2.5 µg/ml) bound P1-coated cells more efficiently than infected 
target cells. Hence, 19.0 ± 0.6% and 59.0 ± 5.8% of P1-A-coated 
cells and 34.0 ± 1.6% and 39.0 ± 3.6% of P1-B-coated cells stained 
positive for 2F5-IgA and 2F5-IgG, respectively, when detected 
with anti-human kappa light chain. As expected, neither 2F5-IgA 
nor 2F5-IgG bound P1-C-coated cells, thus serving as a negative 
control. By using anti-human IgG or IgA for detection, 86.0 ± 2% 
of P1-A and 88.0 ± 1.3% of P1-B-coated cells stained positive for 
2F5-IgA, while >90% stained positive for 2F5-IgG independent 
FigUre 1 | 2F5-IgA and 2F5-IgG bind to P1 Clades A and B in a dose-dependent manner. The specificity of (a) 2F5-IgA (solid line) and (B) 2F5-IgG (dotted line)  
for P1 Clade B (square), Clade A (circle), and Clade C (triangle) was evaluated by ELISA. Mouse anti-human kappa light chain was used for direct comparison of 
both 2F5 isotypes. Specific binding (OD, 450 nm) is plotted as a function of 2F5 antibody (Ab) concentration (ng/ml). No binding was detected for the irrelevant IgA 
or IgG used as negative controls (OD 450 nm: <0.1). Values represent mean ± SEM, derived from three independent experiments performed in duplicate.
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of the clade and again 2F5 isotypes failed to bind P1-C-coated 
cells.
Altogether, HIV-1 Clade A- and B-infected cells, as well as 
P1-coated cells, constitute suitable target cells to assess ADCC 
mediated by 2F5-IgA and 2F5-IgG.
2F5-iga Triggers the lysis of hiV-1-
infected cells by aDcc cross-clade
We first evaluated the capacity of 2F5-IgA to mediate lysis of 
HIV-1 R5-tropic Clade B- and Clade A-infected target lym-
phocytes by ADCC. As initially transmitted viruses are mainly 
R5-tropic, such target cells might mimic cells infected early in 
disease transmission. Target cells were surface labeled with 
PKH26 prior to incubation first with Abs and second with 
effector cells. The ADCC potential of 2F5-IgA was assessed by 
calculating the percentage of infected living (Gag+ or GFP+) 
target cells and calculated according to the formula reported in 
Section “Materials and Methods.” The Ab concentration required 
for ADCC is usually much lower than that used for neutralization 
of HIV-1 cell infection, as we previously showed for 2F5-IgG (9). 
Thus, concentrations of 2F5-IgA and IgG as low as 10–500 ng/
ml were next used to initiate ADCC. 2F5-IgA triggered lysis by 
ADCC of target cells infected by both clade of HIV-1, namely 
A and B, in a concentration-dependent manner, reaching 
16.0 ± 1.3% lysis for Clade B (Figure 2A) and 30.1 ± 4.05% lysis 
of Clade A (Figure 2B). As a negative control, irrelevant IgA or 
IgG induced only a low background lysis of target cells (<2–3%, 
respectively). Increasing Ab concentration to 1.5 µg/ml did not 
increase target cell lysis (data not shown), suggesting that 2F5-IgA 
binding to target cells was saturated at 500 ng/ml. Furthermore, 
2F5-IgG not only induced ADCC of Clade B-infected target cells 
(Figure 2A) as we showed earlier (9) but also induced ADCC of 
Clade A-infected target cells (Figure 2B). At 500 ng/ml, 2F5-IgA 
induced ADCC of both Clade B and Clade A-infected target 
cells with higher efficiency than 2F5-IgG (Clade B: 16.0 ± 1.3% 
versus 9.0 ± 2%, unpaired t-test p < 0.05; Clade A: 30.1 ± 4.05% 
versus 7.86 ± 0.8%, unpaired t-test p < 0.006; Figures 2A,B). In 
contrast, and as expected, HIV-1 Clade C-infected cells were not 
lysed by ADCC by either 2F5 isotypes (data not shown) due to the 
lack of binding to the MPER region as shown above (Figure 1), 
and confirming the specificity of HIV-1 Clade A- and B-infected 
target cell lysis.
Altogether, 2F5-IgA, more efficiently than 2F5-IgG, promotes 
HIV-1 Clade A and B-infected cells lysis by ADCC.
2F5-iga has the Potential to induce the 
lysis of P1 clade a- and clade B-coated 
Target cells by aDcc
To analyze the mechanism by which 2F5-IgA induced ADCC, 
we next used P1-coated target cells that are easier to prepare 
in quantities compared to HIV-1-infected cells. To measure 
ADCC, P1-coated target cells were double labeled with 
PKH26 and carboxyfluorescein diacetate succinimidyl ester 
(CFSE) prior to incubation with Abs followed by addition of 
effector cells, as we reported (9). By using the gating strategy 
described in supplementary Fig. 1, lysed target cells (membrane 
PKH26+, cytosolic CSFE−) are then easily distinguished from 
live target (membrane PKH26+, cytosolic CSFE+) and non-
labeled effector cells. A dose-dependent ADCC-mediated 
lysis of P1-B and P1-A-coated cells was observed for 2F5-IgA 
and 2F5-IgG. At the highest 2F5 concentration (500  ng/
ml), 2F5-IgA induced 32.0 ±  2.51% of P1-B-coated cell lysis, 
whereas 2F5-IgG-mediated 40.1 ±  1.41% of P1-B-coated cell 
lysis; using P1-A-coated cells as targets, 2F5-IgA induced 
52.0 ±  3.1% target cell lysis, similar to 2F5-IgG that induced 
53.0 ±  1% of target cell lysis (Figures  3A,B). As a negative 
control, irrelevant IgA or IgG induced only a low background 
lysis of target cells (<4–5%, respectively). In confirmation of 
ADCC specificity, both 2F5-IgA and 2F5-IgG were unable to 
FigUre 3 | 2F5-IgA and 2F5-IgG induce the lysis of P1-A- and P1-B-coated cells in a dose-dependent manner. The efficacy of 2F5-IgA (solid line, square) and 
2F5-IgG (dotted line, circle) to induce the lysis of P1-B (a), and P1-A coated cells (B) was evaluated by flow cytometry. Target P1 Clade A and B cells were double 
stained with PKH26 and carboxyfluorescein diacetate succinimidyl ester and then incubated with the indicated concentrations of 2F5-IgA or 2F5-IgG for 30 min at 
room temperature (RT), prior to addition of effector monocytes (effector/target ratio: 10:1). Specific lysis determined as we reported (9) is plotted as a function of 2F5 
antibody (Ab) concentration (ng/ml). Values represent mean ± SEM, showing the percentage of specific Ab-dependent cellular cytotoxicity (ADCC) killing derived 
from five independent experiments performed in duplicate. *p < 0.05, **p < 0.02, and ***p < 0.005, unpaired Student’s t-test of 2F5-IgA versus 2F5-IgG mediated 
ADCC.
FigUre 2 | Human immunodeficiency virus-1 (HIV-1)-specific antibody-dependent cellular cytotoxicity (ADCC) triggered by 2F5-IgA compared to 2F5-IgG. Target 
CD4+ T CEM-NKr cells infected with (a) HIV-1 Clade B (JR-CSF) or (B) green fluorescent protein (GFP)-reporter CD4high CCR5high T-cell lines infected with HIV-1 
Clade A (92UG031) were stained with PKH26 and then incubated with the indicated concentrations of 2F5-IgA or 2F5-IgG for 30 min at room temperature (RT), 
prior to addition of effector monocytes (effector:target ratio, 10:1). After 4 h, the percent of infected living (Gag+ or GFP+) target cells was measured by flow 
cytometry. The percent of ADCC was calculated using the formula: 100 × (% of infected/PKH26+ target cells without antibody − % of infected/PKH26+ target cells 
with antibody)/(% of infected/PKH26+ target cells without antibody). Values represent means of HIV-1-infected target cell-specific lysis ± SEM, from six independent 
experiments performed in duplicate or triplicate for each clade, *p < 0.05, **p < 0.02, and ***p < 0.005, unpaired Student’s t-test of 2F5-IgA versus 2F5-IgG-
mediated ADCC.
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bind P1-C (Table 1) and failed to induce P1-C-coated target cell 
lysis (P1-C-coated cell-specific lysis, <0.5%). P1-A-coated cells 
lysis by 2F5-IgA was higher compared to that of P1-B-coated 
cells for all concentrations tested (Figures 3A,B), whereas no 
significant differences between P1-A and P1-B-coated cell lysis 
was induced by 2F5-IgG (Figures 3A,B). Taking into account 
the respective efficiency of 2F5-IgA and 2F5-IgG to bind to P1-A 
and P1-B-coated cells (Table  1), 2F5-IgA-mediated ADCC of 
P1-A-coated target cells was the most robust compared to other 
conditions. Overall, the magnitude of P1-coated lymphocytes 
lysis correlated with the 2F5 isotype binding efficiency to target 
cells reported in (Table 1) (Pearson r = 0.8150, p < 0.05).
FigUre 4 | Antibody-dependent cellular cytotoxicity (ADCC) depends on 
FcαRI and FcγRI. Monocytes were preincubated or not with either anti-CD89- 
or anti-CD64-blocking antibody for 1 h at 37°C before incubation with 
double-stained CD4+ T CEM-NKr cells coated with P1. Target cell lysis was 
evaluated as shown in Figure 3. Values represent the percent of ADCC-
induced cell lysis reduction in the presence of monocytes preincubated with 
anti-CD89 or anti-CD64 antibody. Values represent mean inhibition ± SEM. 
*p < 0.005, unpaired Student’s t-test compared to ADCC in the absence of 
antibodies.
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Altogether, 2F5-IgA mediates specifically ADCC of P1-A- and 
P1-B-, but not P1-C-coated target cells, and the magnitude of 
lysis was higher on P1-A-coated cells.
The aDcc activity of 2F5-iga or 2F5-igg 
Depends on Fcαri or Fcγri
Next, engagement of isotype-specific FcR in ADCC was evalu-
ated by preincubation of monocytes with anti-human CD89 Ab. 
Inhibition with anti-CD89 antibody resulted in a strong decrease 
of P1-A- and P1-B-coated target cell lysis triggered by 2F5-IgA 
(83.0 ±  6% and 52.0 ±  7%, respectively; Figure  4). ADCC of 
both P1-A and P1-B mediated by 2F5-IgG was fully inhibited by 
preincubation with anti-CD64 Ab (Figure 4).
Furthermore, 2F5-IgA binding to effector cells was required 
for triggering ADCC, as preincubation of monocytes with a 
100-fold excess (50 µg) of irrelevant IgA together with 2F5-IgA 
(500 ng/ml) resulted in a 91.0 ± 5% reduction of ADCC induced 
by 2F5-IgA alone.
Thus, IgA-mediated ADCC depends on FcαRI signaling and 
not on alternative Fcα/μR (37). Similarly, IgG-induced ADCC 
depends on FcγRI signaling, as we have already shown (9).
2F5-igg Potentiates 2F5-iga-Mediated 
lysis of P1-a Target cells by aDcc
2F5-IgA and IgG have different epitope affinity and specificity 
(21), suggesting that the two isotypes could simultaneously bind 
to target cells, as we reported for HIV-1-infected Langerhans 
cells (21). Furthermore, as monocyte effector cells express both 
FcαRI and FcγRI, they can bind 2F5-IgA and 2F5-IgG simulta-
neously. We therefore evaluated whether 2F5-IgA and 2F5-IgG 
could mediate in concert the lysis of P1-coated target cells by 
ADCC.
Thus, 10 ng of 2F5-IgA together with 0.2 or 1 ng of 2F5-IgG 
were incubated with P1-A-coated target cells, and ADCC was 
monitored after effector cell addition. In parallel, ADCC induced 
by each isotype alone at the same concentration was evaluated 
(Figure 5A). The addition of 2F5-IgG to 2F5-IgA increased target 
cell lysis compared to 2F5-IgA alone. Furthermore, lysis magni-
tude induced by combining the two 2F5 isotypes was always sig-
nificantly higher than the arithmetic sum of lysis induced by each 
isotype alone at the same concentration (for 10 ng/ml 2F5-IgA 
and 0.2 ng/ml 2F5-IgG: 18.9 ± 3.5% versus 10 ± 2%, Student’s 
t-test p < 0.05; and for 10 ng/ml 2F5-IgA and 1 ng/ml 2F5-IgG: 
38.2 ± 1.9% versus 25.4 ± 3.8%, Student’s t-test p < 0.05). Thus, 
2F5-IgA and 2F5-IgG act in cooperation to lyse P1-A target cells 
by ADCC. We next evaluated whether the cooperation of the two 
isotypes in mediating ADCC was the result of increased P1-A 
target cells binding by each isotype in the presence of the other 
compared to binding by each isotype when incubated alone with 
target cells (Figure  5B). Accordingly, simultaneous incubation 
of P1-A target cells with 2F5-IgA (2.5  µg/ml) and increasing 
concentration of 2F5-IgG (from 0.12 to 0.5 µg/ml) compared to 
incubation with each isotype alone resulted in increased target 
cell binding at all concentrations tested. Of note, increase was 
higher at the lowest IgG concentration [MFI of 2F5-IgA binding 
alone versus in the presence of 2F5-IgG (0.125 μg/ml): 16.8 ± 1.1 
versus 37.2 ±  0.7, Student’s t-test p <  0.001; MFI of 2F5-IgG 
(0.125 µg/ml) binding alone versus in the presence of 2F5-IgA: 
11.5 ± 0.4 versus 21.3 ± 0.4, Student’s t-test p < 0.01]. In contrast, 
no cooperation was detected when P1-B-coated target cells were 
used, most likely due to more efficient binding of 2F5-IgA for 
P1-B relative to P1-A (Table 1), resulting in steric hindrance thus 
reducing 2F5-IgG access to P1-B-coated cells.
We then evaluated the cooperative activity of 2F5-IgA with 
10E8-IgG, another broadly neutralizing Ab specific for a gp41 
epitope contiguous to the 2F5 one and included in the P1 peptide. 
In this case again, 2F5-IgA (100 ng/ml) cooperated with increas-
ing doses of 10E8-IgG (from 1 to 5 ng/ml) to induce an efficient P1 
Clade-B-target cells lysis at all concentrations tested (Figure 5C). 
Lysis magnitude induced by combining the two isotypes was 
significantly higher than the arithmetic sum of lysis induced 
by each isotype alone at the same concentration (for 100 ng/ml 
2F5-IgA and 1 ng/ml 10E8-IgG: 16 ± 0.7% versus 13 ± 0.29%, 
Student’s t-test p <  0.05; for 100  ng/ml 2F5-IgA and 2  ng/ml 
10E8-IgG alone: 22.5 ±  2% versus 16 ±  0.31%, Student’s t-test 
p < 0.05; and for 100 ng/ml 2F5-IgA and 5 ng/ml 10E8-IgG alone: 
36 ± 4.6% versus 31 ± 2.3%, Student’s t-test p < 0.05). As shown 
above for 2F5-IgA and 2F5-IgG, cooperation of 2F5-IgA and 
10E8-IgG (0.125–0.5 µg/ml) in increasing target cell lysis directly 
correlated with an increase in target cell binding (Figure  5D). 
However, in this case, only 2F5-IgA binding increased (MFI of 
2F5-IgA (2.5  µg/ml) alone versus in the presence of 10E8-IgG 
(0.125 μg/ml): 31.8 ± 3.1 binding IgA versus 60.2 ± 5.7, Student’s 
t-test p < 0.1).
FigUre 5 | 2F5-IgA cooperates with 2F5-IgG to induce lysis of P1-A target cells by antibody-dependent cellular cytotoxicity (ADCC) as a result from increased 
binding to target cells. (a,c) CD4+ T CEM-NKr cells coated with P1-A and P1-B and double stained with PKH26/carboxyfluorescein diacetate succinimidyl ester 
were incubated with either 2F5-IgA (black bars), 2F5-IgG or 10E8-IgG (gray bars), or with a combination of both, at indicated concentrations, for 30 min at room 
temperature (RT). Then, effector cells were added at an effector/target ratio of 10:1. Hatched bars represent the experimental values ± SEM of ADCC induced by 
the combination of 2F5-IgA and 2F5-IgG or 10E8-IgG at indicated concentrations. n = 3 independent experiments performed in duplicate. *p < 0.05, Student’s 
t-test between the arithmetical sum of cell lysis induced by each isotype separately and cell lysis induced by both isotype together. (B,D) CD4+ T CEM-NKr cells 
coated with P1-A and P1-B were incubated with 2F5-IgA (black bars), 2F5-IgG or 10E8-IgG (gray bars), or with a combination of both at indicated concentrations 
for 1 h at 4°C. Specific binding was detected using either mouse fluorescein isothiocyanate (FITC)-conjugated anti-human IgA or allophycocyanin (APC)-conjugated 
anti-human IgG, or the combination of both, and analyzed by flow cytometry, as indicated in the Section “Materials and Methods.” Values represent MFI of specific 
binding. n = 5 independent experiments. ***p < 0.0001 and p < 0.0002, **p < 0.001, Student’s t-test between MFI values of the binding of IgA or IgG alone with 
that of IgA or IgG in the combination mix, respectively.
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DiscUssiOn
This study is the first rigorous examination of the ability of an 
anti-HIV-1 envelope IgA to induce the lysis of target cells by 
ADCC cross-clade.
Worldwide, HIV-1 infection occurs predominantly via 
sexual intercourse at mucosal sites. It is thus critical to evaluate 
whether mechanisms additional to neutralization could block 
this transmission pathway. IgA is the prevalent Ab isotype at 
mucosal sites. Furthermore, FcαRI/CD89 was identified on 
phagocytes located in mucosal tissues (25) and monocytes 
that, along with macrophages and neutrophils, are the pre-
dominant FcR bearing cells in the cervicovaginal mucosa (38). 
The present characterization is in line with the new vision 
concerning the importance of Ab isotype profile in HIV-1 
vaccine efficacy and protection in mucosal challenge, such as 
Ab-mediated internalization of HIV-1 virions that was shown 
to differ among Ab isotypes (28). Here, we hypothesized that 
anti-HIV-1 envelope IgA, including neutralizing ones, alone or 
in cooperation with IgG, could induce destruction of infected 
cells by ADCC using monocytes expressing both FcγR and 
FcαR as effector cells.
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2F5-IgA was used for three main reasons: first because 
2F5-IgA offers a model of a neutralizing gp41-specific IgA for 
which no Fc-mediated antiviral functions, including ADCC, have 
been studied. Thus, evaluation of the ADCC potential of a NAb 
IgA will provide information concerning the contribution of the 
Fc region of gp41-specific IgA in the protection against HIV-1; 
second, as we reported earlier using P1-coated cells and HIV-1 
infected cells as targets, 2F5-IgG elicits ADCC in a mechanism 
strictly dependent on binding to ELDKWA, the canonical 2F5 
epitope on Clade B HIV-1 exposed on the target cell (9), and on 
FcγRI expressed on monocytes served as effector cells; third, this 
evaluation complements the comparative analysis of anti-HIV-1 
functional properties of two isotypes, IgA and IgG, of the same 
Ab 2F5. Hence, we previously demonstrated (21) that, although 
harboring the same VH regions and light chain as 2F5-IgG, 
2F5-IgA has increased antigen affinity for gp41 and HIV-1 viruses 
due to a difference in fine epitope specificities and increased Fab-
dependent antiviral activities against Clade B HIV-1.
Here, we demonstrate for the first time that 2F5-IgA can 
trigger ADCC of target cells present at different steps of HIV 
infection (39). Hence, HIV-1 envelope subunit-coated target 
cells, an experimental model frequently used in ADCC studies 
by us (9, 19, 30–32) and others (33–35), could recapitulate the 
initial step in infection, when viruses bind to target cells exposing 
specific epitopes poorly accessible at the free virus surface (40). 
Alternatively, HIV-1-infected cells represent targets once infec-
tion is established, although in this case, CD4 downregulation 
and Tetherin/BST-2 antagonism could reduce HIV envelope 
ADCC-mediating epitope exposure (41).
In addition, our results provide a comprehensive comparative 
analysis of the 2F5-IgA and 2F5-IgG revealing additional isotype-
specific links between defined Fc and antigen-binding domains. 
Although much is known about the role of variable domains in 
the neutralization breadth and potency of 2F5 as IgA and IgG, 
the contribution of Fc-domains to their activities is, by contrast, 
poorly characterized for 2F5-IgG and has never been character-
ized for IgA.
Indeed, in vivo, the Ab antiviral efficiency is highly dependent 
not only on the Fab–antigen interactions that block viral entry 
but also on interaction of the Ab Fc-domain with its cognate 
FcR expressed on the innate effector cells (37). By combin-
ing the action of the Fab and Fc regions, Abs mediate a broad 
array of Fc-dependent effector functions including ADCC, 
Ab-dependent virus inhibition (ADCVI), and ADCP, in addition 
to neutralization.
Remarkably complex, Fc-mediated functions link the specific 
adaptive immune system to the powerful effector functions of 
the innate immune system and depend critically on Ab isotype. 
Effector functions of IgA could differ from the ones of IgG due 
to differences in Fc-affinity for corresponding FcαR versus 
FcγR and the lack of IgA binding by the C1q component of 
complement. Furthermore, Ab binding to FcR is not sufficient 
for ADCC to occur, but also requires triggering of effector cell 
degranulation. Accordingly, IgA mediates ADCC by monocytes, 
but in contrast to IgG, and although IgA binds to NK cells, FcαR 
stimulation by IgA failed to trigger ADCC on NK cells [data not 
shown and (15)].
Here, the profile of 2F5-IgA and 2F5-IgG binding to their 
respective FcR, FcαRI, and FcγRI was similar (Table 1) and had 
no impact in triggering ADCC. Rather, the target antigen, P1-A 
versus P1-B, influences the extent of ADCC. A positive correla-
tion between isotype binding to target cells and isotype-specific 
ADCC was observed for both P1 clades. Likewise, ADCC of 
infected cells mediated by 2F5-IgA and 2F5-IgG appeared less 
efficient than that of P1-coated target cells, in direct association 
with differences in target cell binding (Table 1). These differences 
correspond to a limited exposure of the Ab cognate epitopes at the 
infected cell surface, a likely consequence of incomplete or incor-
rectly folded envelope protein at cell surface expression commonly 
reported on infected cells (42), compared to P1-coated cells. In 
addition, during the 4 h of the assay, infected cells do release free 
viral particles to which Abs could also bind, in turn limiting the 
Ab availability for target cell binding and subsequent ADCC. This 
suggests that additional Fc-mediated functions such as phagocy-
tosis of IgA or IgG opsonized viral particles by the effector cell 
might compete with 2F5-IgA and 2F5-IgG-dependent ADCC, 
leading to a lower percentage of infected cell lysis.
Of note, 2F5-IgA mediates HIV-1-infected cell lysis more effi-
ciently than IgG, whereas the opposite is observed for P1-coated 
cells. These differences are in good correlation with the target 
cell binding efficiencies shown in Table 1 reporting that 2F5-IgG 
binds better to P1-coated cell than 2F5-IgA, whereas 2F5-IgA 
binding to HIV-infected cells is superior compared to 2F5-IgG. 
Therefore, one likely explanation for the difference in ADCC-
mediated lysis hierarchy between the two isotypes is the differ-
ence in isotypes binding to ADCC target cells.
Clade A is widely distributed worldwide, and the number of 
Clade A-infected individuals exceeds that infected by Clade B. 
However, Clade A HIV-1 is poorly studied. The MPER region 
targeted by 2F5 is well conserved in A and B clades, unlike in 
Clade C, and equally recognized by the 2F5 isotypes. Therefore, 
the cross-clade ADCC mediated by 2F5-IgA and 2F5-IgG 
against P1-B and P1-A-coated target cells constitutes an impor-
tant antiviral mechanism beyond neutralization that warrant 
attention in antiviral strategies such as vaccines or passive 
immunotherapies.
Human immunodeficiency virus-1 infection largely occurs 
through mucosal epithelium, and persistent reservoirs likely 
form and hide in mucosal tissues (43). IgAs are the first line of 
defense at mucosal surfaces. Mucosal IgA might thus induce the 
lysis of target cells, either prior to infection when the virus is 
surface bound or when actually CD89 infected (39), by ADCC 
through engagement of the Fcα receptor. All forms of IgA have 
been shown to bind FcαRI/CD89 (44), suggesting that our results 
may also apply to dimeric IgA2, the main IgA isotype at mucosal 
sites as well as to dimeric IgA1. FcαRI/CD89 is identified not only 
on a variety of cell types within the immune system but also on 
phagocytes located in mucosal areas where IgA is the prevalent 
Ab isotype (43, 45). Accordingly, serum and secretory IgA Abs 
from HIV-infected individuals can lyse X4 HIV-1-infected cells, 
although in this study epitope specificity was not studied (46). 
Our present results thus provide a new perspective on the role 
of IgA in protection against mucosal HIV-1 acquisition, by sug-
gesting that the induction of IgA by vaccination, in particular 
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targeting gp41, might strengthen protection by complementary 
and combined activities with IgG.
Similar levels of IgA and IgG are detected at the vaginal 
mucosa, and IgA is quantitatively the second most abundant 
class of Ab in the blood. The concurrent antiviral functions of 
IgA and IgG against HIV-1 have been poorly studied. Early 
studies on the mucosal immune response in a non-HIV context 
reported that the addition of secretory IgA to IgG increased 
IgG-dependent ADCC mediated by monocytes, the two isotypes 
acting in cooperation (47). We now demonstrate that concern-
ing HIV-1, 2F5-IgA cooperates not only with 2F5-IgG but also 
with 10E8-IgG, another broadly neutralizing gp41-specific Ab, 
to increase cell lysis by ADCC. In both cases, 2F5-IgA binding to 
target cells is increased in the presence of the IgG, either 2F5 or 
10E8. Improved cell lysis could thus result from the recognition of 
one target cell by the two different isotypes. In turn, both isotypes 
either bind to different effector cells or alternatively to a single 
one expressing both FcαR and FcγR. The RV144 clinical trial 
analysis also addressed the interference of IgA- in IgG-mediated 
ADCC. There, vaccine-raised serum gp120-specific IgA blocked 
gp120-specific IgG-mediated gp120-coated cell lysis ADCC, 
most likely due to higher affinity of the IgA than the IgG for gp120 
(17). Several although not exhaustive reasons can be proposed to 
explain this apparent discrepancy with the cooperation between 
isotypes we report here. First, in their ADCC model, Tomaras 
et  al. used effector cells that did not expressed the FcαRI and 
were thus unable to lyse target cell mediated by IgA, although IgA 
bound efficiently target cells and displaced IgG binding. Thus, 
one cannot exclude that if effector cell would have expressed the 
FcαRI, this high affinity IgA would have increased IgG-mediated 
ADCC rather than just decreasing it due to IgG displacement 
(17). Second, concentrations of Abs used in Tomaras’ study are 
10- to 100-fold higher than that used in the experiments reported 
here. This difference could participate in the divergent results of 
the two studies. Third, the capacity of the gp120 epitopes targeted 
by the RV144 vaccine-induced Abs in mediating ADCC differs 
from that of the gp41 epitopes, suggesting that the epitopes tar-
geted by the Ab is of chief importance for isotype cooperation in 
ADCC (48). Fourth, divergences observed could also result from 
differences in Ab glycosylation as IgG, but not IgA, glycosyla-
tion pattern has been shown to impact FcR binding/affinity and 
antibody-mediated cell function (49, 50).
Nevertheless, the cooperation in ADCC between isotypes 
targeting gp41 we report here is in line with the cooperation in 
blocking HIV-1 transfer from LCs to T-cells that we observed 
previously (21), and with in vivo studies reporting on the coop-
eration between anti-HIV-1 gp120-IgG and corresponding IgA 
obtained by genetic engineering that when infused in monkey, 
completely protected animals against intrarectal virulent SHIV 
challenge (51), whereas each Ab alone resulted in partial 
protection.
In conclusion, our present study clearly demonstrates that not 
only 2F5-IgG is provided with an ADCC potential but also that 
IgA, such as gp41-specific 2F5-IgA, can induce the lysis of target 
cells by ADCC cross-clade. Our study emphasizes the critical 
value of inducing IgA and IgG Abs in the mucosa with comple-
mentary and cooperative activities by vaccination. Both isotypes 
together could combine suboptimal defenses at the mucosal and 
systemic levels to completely prevent virus acquisition (51).
Furthermore, similar to the ADCC-inducing Abs that 
develop earlier in HIV-1-infected patients than do neutralizing 
Abs (3), additional antiviral activities involving the Fcα and γ 
region of Abs that are induced by vaccination may also appear 
earlier after contact of the host with the virus. Hence, inducing 
both IgA and IgG by vaccination and assessing vaccine efficacy 
by measuring IgA and IgG Fc-mediated functions emerge as a 
crucial goal in antiviral strategies.
MaTerials anD MeThODs
Monoclonal abs and Peptides
2F5-IgA2 (2F5-IgA) and IgG1 (2F5-IgG) were obtained as 
previously described (21). Non-specific IgA and IgG controls 
were from The Binding Site Group Ltd. (Birmingham, UK) 
and Jackson ImmunoResearch Europe Ltd. (Suffolk, CB8 7SY, 
UK), respectively. Peptide P1 (aa 650–685) derived from gp41 
envelope subunit of Clade B (P1-B) was from HXB2 HIV-1: 
SQTQQEKNEQELLELDKWASLWNWFDITNWLWYIK 
(30), of Clade A (P1-A) was from 99UGA07072 HIV-1: 
SQIQQKKNEQDLLALDKWANLWNW-FDISNWLWYIR, and 
of Clade C (P1-C) was from Bw96Bw0502 HIV-1: SQTQQEKNEQ-
ELLALDSWKNLWNWFSITNWLWYIK. Peptides were chemi-
cally synthesized [purity > 95%, Biopeptide (LA, USA) for P1-B 
and United BioSystems (VA, USA) for P1-A and P1-C].
hiV-1 Viruses
Viruses were from the NIH AIDS Reagent Program: the HIV-1 
JR-CSF (clade B, R5-tropic) expression plasmid was used for 
JR-CSF HIV-1 virus stock production by transfection of 293T cells 
as previously described (52), whereas the HIV-1 primary isolate 
92UG031 (clade A, R5) was amplified on peripheral blood mono-
nuclear cells (PBMCs), as previously described (21).
effector cells
Primary human monocytes were purified from healthy donor 
PBMC by negative selection using human monocyte enrichment 
kits (StemCell Technologies, France). For each experiment, a 
pool of PBMCs from three different donors were used to purify 
monocytes to limit donor variability. Resulting monocytes were 
FcγRIII negative (data not shown).
Target cells
Human CD4+T CEM-NK-resistant (CEM-NKr) lymphocytic 
cells line expressing CCR5 were obtained from the NIH AIDS 
Reagent Program. The CD4high CCR5high GFP-reporter T-cell 
line (53) was a kind gift from Dr O. Kutsch (The University 
of Alabama at Birmingham). To prepare infected target cells 
for ADCC, 3 ×  106 CEM-NKr lymphocytes were infected with 
800 ng p24 of JR-CSF and GFP-reporter cells with 600 ng p24 of 
HIV-1 clade A (92UG031) for 2 h at 37°C and further cultured 
for 40 h. Infection was monitored by intracellular p24 detection 
as described in Ref. (52) or by monitoring GFP fluorescence by 
flow cytometry resulting in 40–50% infected (p24+) viable cells 
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for Clade B and 8–20% infected (GFP+) for Clade A, an infection 
level required to obtain consistent ADCC levels.
Alternatively, CEM-NKr cells (1 × 106 cells) were coated with 
P1-A, P1-B, or P1-C (2.5 µM) for 1 h at room temperature (RT) 
as described (9).
recognition of P1-a, P1-B, and P1-c  
by 2F5-iga and 2F5-igg
Evaluation of 2F5-IgA and 2F5-IgG binding to P1-A, P1-B, and 
P1-C peptides was performed by ELISA as described (21) by coat-
ing microtiter plates (Peptide Immobilizer, Exiqon) with appro-
priated P1 (100 ng/well) overnight at 4°C in PBS. Comparative 
Ab binding at indicated concentrations was detected using 
a biotinylated mouse anti-human Ig kappa light chains (BD 
Pharmingen) followed by streptavidin-HRP.
ab Binding to Target cells
For detection of HIV-1 envelope on HIV-1-infected target cells, 
or P1 on P1-coated target cells, 2F5-IgA or 2F5-IgG (2.5 µg/ml) 
were incubated with 105 target cells prepared, as described above, 
for 1 h at 4°C or 45 min at RT, respectively, followed by either 
fluorescein isothiocyanate (FITC)-conjugated goat anti-human 
IgA or IgG (Jackson ImmunoResearch, West Grove, PA, USA) 
at 10 µg/ml, allophycocyanin-conjugated goat anti-human IgA 
or donkey anti-human IgG (Jackson ImmunoResearch, West 
Grove, PA, USA) or FITC-conjugated mouse anti-human kappa 
light chain (BD Biosciences, San Jose, CA, USA), as indicated 
by the manufacturer. Alternatively when indicated, anti-IgA2 
[The Binding Site Group Ltd. (Birmingham, UK)] was used as 
secondary Ab. In the case of infected target, cells were next 
fixed with 4% paraformaldehyde, and HIV-1 clade B-infected 
cells were further stained for intracellular Gag with the phy-
coerythrin (PE)-coupled anti-Gag KC57 murine monoclonal 
Ab (Beckman Coulter GmbH), whereas GFP fluorescence was 
used to monitor HIV-1 clade A infection in GFP-reporter target 
cells.
Antibody binding to target cells was quantified by flow cytom-
etry using a Guava EasyCyte flow cytometer (Merck-Millipore) 
and analyzed using the dedicated InCyte software.
ab Binding to effector cells
The specificity of 2F5-IgA and 2F5-IgG binding to monocytes 
FcαR or FcγR was evaluated by incubation of 2.5 µg/ml Abs with 
105 monocytes for 1 h at 4°C, followed by either FITC-conjugated 
mouse anti-human kappa light chain or alternatively by anti-
human IgA2 or anti-human IgG-FITC as mentioned above.
Antibody binding to effector cells was quantified by flow 
cytometry using a Guava EasyCyte flow cytometer (Merck-
Millipore) and analyzed using the dedicated InCyte software.
Phenotyping Fcr on Monocytes
For FcαR or FcγR detection on effector cells, 105 freshly isolated 
monocytes were incubated with PE-mouse IgG1k anti-human 
FcαRI (CD89) or with FITC mouse IgG1k anti-human FcγRI 
(CD64) mAbs, as indicated by the manufacturer (BD Biosciences, 
USA). Specific labeling was quantified by flow cytometry using 
a Guava EasyCyte (Merck-Millipore) and analyzed using the 
dedicated InCyte software.
aDcc assays
 (i) ADCC using infected cells as targets: ADCC was determined 
using an adaptation from Ref. (10). Briefly, HIV-1-infected 
cells were labeled with the membrane dye PKH26 (Sigma-
Aldrich, St. Louis, MO, USA) as recommended by the 
manufacturers and incubated in triplicated wells with 
2F5-IgA and 2F5-IgG at indicated concentrations or the 
irrelevant IgA2 or IgG1 for 30 min at RT. Effector monocytes 
were then added at a 10:1 effector/target ratio. Plates were 
spun 1  min at 300  g to promote cell contacts and further 
incubated for 4  h at 37°C in a 5% CO2. Co-cultures were 
then fixed with 4% paraformaldehyde. Then, HIV-1 Clade 
B-infected CEM-NKr were stained for intracellular Gag 
with the FITC-coupled anti-Gag KC57 murine monoclonal 
Ab (Beckman Coulter GmbH), whereas GFP expression 
was used to quantify HIV-1 Clade A-infected target cells. 
Cells were immediately acquired on a Guava easyCyte flow 
cytometer (Merck-Millipore), and the frequencies of Gag+ or 
GFP+ cells among PKH26+ cells were determined. ADCC is 
calculated using the following formula: 100× (% of Gag+ or 
GFP+/PKH26+ target cells without Ab − % of Gag+ or GFP+/
PKH26+ target cells with Ab)/(% of Gag+ or GFP+/PKH26+ 
target cells without Ab). Irrelevant IgA or IgG Abs gave a 
background ADCC of 3 and 2%, respectively.
(ii) ADCC using P1-coated cells as targets: ADCC was deter-
mined using an adaptation from Ref. (54), as previously 
described for 2F5-IgG (9). Briefly, after coating with different 
P1 peptides, cells were dually labeled with the membrane 
dye PKH26 and the viability dye 5-(and dye-6-) CFSE 
(Molecular Probes, Eugene, OR, USA) as recommended by 
the manufactures, before incubation with 2F5-IgA, 2F5-IgG, 
or the irrelevant IgA or IgG for 30 min at RT. Effector Cells 
were then added, at a 10:1 effector/target ratio; plates were 
spun 1 min at 300 g to promote cell contacts, and further 
incubated for 4 h at 37°C. Flow cytometry dot plot of dual-
stained target cells incubated in the same conditions as the 
effector-target co-cultures were used to set the gate of living 
double-positive target cells, in which the cell membrane 
is still intact. Target cell lysis by monocytes was defined 
by the loss of CFSE but the retention of PKH26 resulting 
in the emergence of a lysed PKH26+CFSE− population within 
the PKH26+ gate (i.e., % of CFSE− cells within PKH26 high 
gate), as we described (9). Irrelevant IgA or IgG Abs at 
500  ng/ml (the highest concentration) gave a background 
ADCC of 4 and 3%, respectively.
Fcr Blockade
When indicated, FcRs CD89 or CD64 were blocked by preincu-
bation of monocytes effector cells with a blocking anti-human 
CD89 monoclonal Ab (MIP7c) (Abcam, France) or a blocking 
anti-human CD64 monoclonal Ab (BD Pharmingen, USA) 
at 10 µg/ml at 37°C for 1 h prior to being mixed with ADCC-
inducing Abs and target cells. Percentage blocking is calculated 
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using the formula 100× (% of ADCC with blocking/% ADCC 
without blocking).
statistical analysis
Statistical significance was analyzed by the two-tailed Stu dent’s 
t-test using Prism 5 (GraphPad, San Diego, CA, USA) software.
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